The dream of a cancer treatment that is as unique as the patient is becoming a reality through Personalized cancer treatment . This approach moves away from a one-size-fits-all model to a strategy that considers the individual's genetic makeup, lifestyle, and the specific molecular characteristics of their tumor. By tailoring treatment to the individual, personalized cancer treatment aims to maximize efficacy and minimize side effects. The global targeted cancer therapies market, valued at USD 335.42 billion in 2025 and projected to grow to USD 912.18 billion by 2035, is a direct result of this paradigm shift.

Personalized cancer treatment is a multi-step process that begins with a comprehensive analysis of the patient's tumor. This includes genomic sequencing to identify specific mutations, gene expression profiling to understand which genes are active, and potentially other molecular tests. This information is then used to select the most appropriate treatment, which may include a targeted therapy, immunotherapy, or a combination of modalities. The goal is to match the right drug to the right patient. This approach has been particularly successful in treating cancers like non-small cell lung cancer, where testing for EGFR, ALK, and ROS1 mutations is standard practice, and in breast cancer, where HER2 status guides treatment.

The Role of Biomarkers in Personalization

Biomarkers are the cornerstone of personalized cancer treatment. They are measurable indicators of a biological state that can be used to predict how a patient will respond to a particular therapy. This can include genetic mutations, protein expression levels, or other molecular features. The use of biomarkers has become routine in clinical oncology for many cancers. For example, the presence of the BRAF V600E mutation in melanoma indicates that the patient is likely to respond to BRAF inhibitors. The development of new biomarkers is an active area of research, with the goal of providing even more precise information to guide treatment decisions. The expansion of biomarker-driven therapies is a key driver of the personalized cancer treatment market.

Future Trends in Personalized Oncology

The future of personalized cancer treatment is focused on integrating multiple layers of data to create a comprehensive picture of each patient's disease. The use of artificial intelligence and machine learning is enabling the analysis of complex datasets to predict treatment response and identify new therapeutic targets. The development of liquid biopsies is allowing for non-invasive monitoring of tumor evolution and the emergence of resistance. There is a growing focus on using personalized treatment approaches in the neoadjuvant (before surgery) and adjuvant (after surgery) settings. As the field continues to evolve, Personalized cancer treatment will become even more integral to oncology.